Porównanie bezpieczeństwa i immunogenności szczepionki 426c.Mod.Core-C4b z adiuwantem 3M-052-AF + ałunem u niemowląt narażonych na okołoporodową ekspozycję na wirusa HIV, które od urodzenia nie są zakażone wirusem HIV (HVTN316)
Badanie kliniczne I fazy mające na celu ocenę bezpieczeństwa i immunogenności szczepionki 426c.Mod.Core-C4b z adiuwantem 3M-052-AF + ałunem u niemowląt z okołoporodową ekspozycją na wirus HIV, które od urodzenia nie były zakażone wirusem HIV
The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth
Przegląd badań
Status
Warunki
Szczegółowy opis
This study will compare the safety and immunogenicity of an experimental HIV vaccine in infants with perinatal HIV exposure who are without HIV at birth. The study vaccine is called 426c.Mod.Core-C4b. The vaccine is mixed with an adjuvant called 3M-052-AF + Alum.
This study is divided into 2 parts: Part A and B. Part A has 4 groups, while Part B has 2 groups. Part A of the study is testing the vaccine alone or in combination with different doses of adjuvant. Part B is testing study vaccine and the safest dose of adjuvants from Part A versus placebo. Depending on their group, participants will receive 426c.Mod.Core-C4b, 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum, or a placebo by injection at Months 0, 3, and 7.
Additional study visits will occur at Day 1, Week 2, Month 3 1/2, Month 7 1/2, Month 10, Year 1, Year 1 1/2, and Year 1 3/4. Study visits may include physical exams, blood and saliva collection for the infants and questionnaires, counselling, blood, and optional breastmilk collection for the mothers of infants.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Clinical Trials Manager
- Numer telefonu: (206) 667-4212
- E-mail: itindale@fredhutch.org
Lokalizacje studiów
-
-
Gauteng
-
Soweto, Gauteng, Afryka Południowa, 1862
- Soweto HVTN CRS
-
Kontakt:
- Fatima Laher
- Numer telefonu: 27-11-9899700
- E-mail: laherf@phru.co.za
-
Kontakt:
- Leonie Kruger
- Numer telefonu: 27-11-9899700
- E-mail: krugerl@phru.co.za
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria: Mother
- Mother's age is at least 18 years and is willing and able to provide written informed consent for their and their infant's participation in this study
- Mother is in the second or third trimester of singleton pregnancy, as determined by a clinical exam or sonography and reported menstrual history
- Mother agrees to donate umbilical cord blood
- Mother has a planned Caesarian delivery at Chris Hani Baragwanath Academic Hospital (Soweto) and plans to remain in the area after delivery and through study duration
- Mother is determined by the site investigator to be in good overall health at the time of delivery based on medical history and physical exam
- Mother has a documented CD4 count of more than 350 cells/mcL at screening
- Mother has been on cART for at least 16 weeks prior to delivery and intends to continue with cART for the duration of breastfeeding
- Mother has a viral load of less than 400 copies/mL between 2 weeks before and 7 days after delivery
- Mother has access to the participating HVTN CRS and is willing to be followed for the planned duration of the study
- Mother demonstrates understanding of this study and is able and willing to complete the informed consent process and delivery with verbal demonstration of understanding of all questionnaire items answered incorrectly
- Mother agrees not to enroll either self or infant in another research study for the duration of the trial without prior approval of the HVTN 316 PSRT.
- Mother has confirmed positive HIV-1 status documented by medical records at any time during or prior to screening, and confirmed by the HVTN CRS by serology
Exclusion Criteria: Mother
- Any World Health Organization (WHO) grade IV illness within 1 year prior to study enrollment, as determined by the history and physical examination and review of the medical record (if available). These include HIV wasting syndrome; PJP pneumonia; cerebral toxoplasmosis; extrapulmonary cryptococcosis; progressive multifocal leukoencephalopathy; any disseminated endemic mycosis (histoplasmosis); candidiasis of the esophagus, trachea, bronchi, or lung; disseminated atypical mycobacteria; non-typhoid salmonella septicemia; extrapulmonary tuberculosis; lymphoma; and Kaposi's sarcoma.
- Prior participation in any HIV-1 vaccine or anti-HIV antibody-mediated prevention trial
- Receipt of any investigational agent during this pregnancy
- Receipt of blood products, immunoglobulin (Ig), or immunomodulating therapy within 45 days prior to, and the day of delivery
- Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, assessment of infant safety or reactogenicity, or a volunteer's ability to give informed consent
- Any condition that places the newborn at higher risk of early-onset sepsis, such as concern for active maternal infection at delivery, as determined by local site investigators (eg, fever)
- Detectable hepatitis B surface antigen (HBsAg)
Inclusion Criteria: Infant
- Born via Caesarean delivery to a pregnant woman living with HIV-1 who meets all maternal inclusion/exclusion criteria listed above
- Estimated gestational age at birth is at least 37 weeks
Note: If gestational age at birth is not documented in the infant's available birth records, study staff may assess gestational age at the earliest possible opportunity during the screening period and use this assessment for purposes of eligibility determination.
- Weight at birth is at least 2.5 kg
- Has initiated ARV prophylaxis consistent with current site-specific standard of care
- Hemoglobin (HgB) more than 14.0 g/dL
- White blood cell (WBC) count ≥ 7,000 cells/mm3
- Platelets more than 100,000 cells/mm3
- Alanine aminotransferase (ALT) less than 1.25 times upper limit of age-adjusted normal
- Creatinine less than 1.1 times upper limit of age adjusted normal
- Negative HIV-1 nucleic acid test (NAT) on specimen drawn within 72 hours of birth
- Written informed consent provided by mother
- Age is equal to or less than 7 days
Exclusion Criteria: Infant
- Any clinically significant congenital anomaly/birth defect
- Documented or suspected serious medical illness, infection, clinically significant finding from physical examination, or immediate life-threatening condition, including requirement for ongoing supplemental oxygen, as judged by the examining clinician
- Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG), but it does not require exclusion of infants who receive hepatitis B vaccine in the newborn period.
- Receipt of any other investigational product
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part A, Group 1: 426c.Mod.Core-C4b (20 mcg)
Participants will receive 426c.Mod.Core-C4b (20 mcg) alone to be administered as two 0.25-mL intramuscular (IM) doses, one into each thigh at weeks 0, 12, and 28. |
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen. |
|
Eksperymentalny: Part A, Group 2: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.3 mcg) + Alum (250 mcg)
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.3 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28. |
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen. 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF. |
|
Eksperymentalny: Part A, Group 3: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.75 mcg) + Alum (250 mcg)
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.75 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28. |
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen. 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF. |
|
Eksperymentalny: Part A, Group 4: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (1.5 mcg) + Alum (250 mcg)
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (1.5 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28. |
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen. 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF. |
|
Aktywny komparator: Part B, Group 5: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (TBD)* + Alum (250 mcg)
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (TBD) and Alum (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28. |
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen. 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF. |
|
Komparator placebo: Part B, Group 6: Placebo
Participants will receive Placebo (Tris Sodium Chloride (NaCl) buffer ) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28. |
Tris-NaCl buffer. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants reporting local reactogenicity signs and symptoms and number of local reactogenicity signs and symptoms experienced by each participant
Ramy czasowe: Measured through 14 days following receipt of study product at day 5, week 12, and week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 14 days following receipt of study product at day 5, week 12, and week 28
|
|
Number of participants reporting systemic reactogenicity signs and symptoms symptoms and number of systemic reactogenicity signs and symptoms experienced by each participant,
Ramy czasowe: Measured through 14 days following receipt of study product at day 5, week 12, and week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 14 days following receipt of study product at day 5, week 12, and week 28
|
|
Number of participants reporting adverse events and overall number of adverse events
Ramy czasowe: Measured through out the study period
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through out the study period
|
|
Number of participants reporting serious adverse events and overall number of serious adverse events
Ramy czasowe: Measured through 12 months post last vaccination at week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 12 months post last vaccination at week 28
|
|
Number of participants reporting medically attended adverse events and overall number of medically attended adverse events
Ramy czasowe: Measured through 12 months post last vaccination at week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 12 months post last vaccination at week 28
|
|
Number of participants reporting adverse events of special interest (AESIs) that are Potential Immune Mediated Medical Conditions (PIMMCs) and overall number of AESIs that are PIMMCs
Ramy czasowe: Measured through 12 months post last vaccination at week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 12 months post last vaccination at week 28
|
|
Number of participants reporting AEs leading to early participant withdrawal or permanent discontinuation
Ramy czasowe: Measured through 12 months post last vaccination at week 28
|
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [March 2017] |
Measured through 12 months post last vaccination at week 28
|
|
Response rate of CD4bs-specific IgG binding antibodies
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by binding antibody multiplex assay (BAMA) |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Magnitude of CD4bs-specific IgG binding antibodies
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by binding antibody multiplex assay (BAMA) |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Response rate of CD4bs-specific memory B cells
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by flow cytometry |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Magnitude of CD4bs-specific memory B cells
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by flow cytometry |
Measured 2 weeks after the 3rd vaccination at week 28
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Response rate of serum Ab neutralization of vaccine-matched viruses
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by TZM-bl pseudoneutralization assay |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Magnitude of serum Ab neutralization of vaccine-matched viruses
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by TZM-bl pseudoneutralization assay |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Differential neutralization of HIV-1 strains that are diagnostic for CD4bs bNAb precursors
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by TZM-bl assay |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Response rate of serum Ab neutralization of heterologous HIV-1 strains
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by TZM-bl assay |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Magnitude of serum Ab neutralization of heterologous HIV-1 strains
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by TZM-bl assay |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Response rate (i.e., percentage) of CD4bs-specific, including VRC01-class, B cells
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by BCR sequencing of sorted B cells |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Magnitude of CD4bs-specific, including VRC01-class, B cells
Ramy czasowe: Measured 2 weeks after the 3rd vaccination at week 28
|
Measured by BCR sequencing of sorted B cells |
Measured 2 weeks after the 3rd vaccination at week 28
|
|
Response rate of vaccine-specific and CD4bs-specific binding antibodies
Ramy czasowe: Measured 6 months and 12 months after the 3rd vaccination at week 28
|
Measured by BAMA |
Measured 6 months and 12 months after the 3rd vaccination at week 28
|
|
Magnitude of vaccine-specific and CD4bs-specific binding antibodies
Ramy czasowe: Measured 6 months and 12 months after the 3rd vaccination at week 28
|
Measured by BAMA |
Measured 6 months and 12 months after the 3rd vaccination at week 28
|
|
Response rate of CD4bs-specific memory B cells
Ramy czasowe: Measured 6 months and 12 months after the 3rd vaccination at week 28
|
Measured by flow cytometry |
Measured 6 months and 12 months after the 3rd vaccination at week 28
|
|
Response rate of serum neutralization
Ramy czasowe: Measured 6 months and 12 months after the 3rd vaccination at week 28
|
Measured by TZM-bl assay |
Measured 6 months and 12 months after the 3rd vaccination at week 28
|
|
Magnitude of serum neutralization
Ramy czasowe: Measured 6 months and 12 months after the 3rd vaccination at week 28
|
Measured by TZM-bl assay |
Measured 6 months and 12 months after the 3rd vaccination at week 28
|
|
EPI vaccine-specific binding antibody responses
Ramy czasowe: Measured 2 weeks, 6 months, and 12 months after the 3rd vaccination at week 28
|
Assessed by Pediatric Vaccine Multiplex Assay (PVMA) |
Measured 2 weeks, 6 months, and 12 months after the 3rd vaccination at week 28
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Krzesło do nauki: Amy Violari, Perinatal HIV Research Unit
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Infekcje przenoszone przez krew
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu odpornościowego
- Infekcje
- Zakażenia wirusem RNA
- Choroby wirusowe
- Choroby zakaźne
- Choroby przenoszone drogą płciową, wirusowe
- Choroby przenoszone drogą płciową
- Infekcje lentiwirusowe
- Zakażenia Retroviridae
- Zespoły niedoboru odporności
- Zakażenia wirusem HIV
- Siarczan glinu
Inne numery identyfikacyjne badania
- HVTN 316
- UM1AI068614 (Grant/umowa NIH USA)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .